drugset / Trial / NCT02853136

Influence of Fluvoxamine on the Pharmacokinetics of BI 409306

NCT02853136

Phase 1 Completed 18 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

To investigate the influence of fluvoxamine on the pharmacokinetics of BI 409306

Timeline

Start
2016-08-25
Primary completion
2016-10-17
Completion
2016-10-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluvoxamine Unknown 100 mg Oral
Subject OSORESNONTRINE Small molecule 3 mg Oral
Subject OSORESNONTRINE Small molecule 10 mg Oral

Indications

No indication recorded.